Comparative study of rivastigmine and galantamine on the transgenic Drosophila model of Alzheimer's disease
Open Access
- 31 July 2022
- journal article
- research article
- Published by Elsevier in Current Research in Pharmacology and Drug Discovery
- Vol. 3, 100120
Abstract
No abstract availableKeywords
All Related Versions
Funding Information
- Council of Scientific and Industrial Research, India (37(1721)/19/EMR-II)
This publication has 79 references indexed in Scilit:
- Widespread aggregation of mutant VAPB associated with ALS does not cause motor neuron degeneration or modulate mutant SOD1 aggregation and toxicity in miceMolecular Neurodegeneration, 2013
- Antioxidant Therapies for Alzheimer's DiseaseOxidative Medicine and Cellular Longevity, 2012
- Assaying Locomotor, Learning, and Memory Deficits in Drosophila Models of NeurodegenerationJournal of Visualized Experiments, 2011
- Revisiting the role of acetylcholinesterase in Alzheimer’s disease: cross-talk with P-tau and β-amyloidFrontiers in Molecular Neuroscience, 2011
- Grape Extract Protects Mitochondria from Oxidative Damage and Improves Locomotor Dysfunction and Extends Lifespan in a Drosophila Parkinson's Disease ModelRejuvenation Research, 2009
- Quantification of protein modification by oxidantsFree Radical Biology and Medicine, 2009
- Drosophila Models of Neurodegenerative DiseasesAnnual Review of Pathology: Mechanisms of Disease, 2009
- Oxidative DNA damage in mild cognitive impairment and late-stage Alzheimer's diseaseNucleic Acids Research, 2007
- Progressive loss of cortical acetylcholinesterase activity in association with cognitive decline in Alzheimer's disease: A positron emission tomography studyAnnals of Neurology, 2000
- RivastigmineDrugs & Aging, 1998